Talquetamab

Research use only, not for human use.

Talquetamab (JNJ-64407564) is a GPRC5D bispecific antibody for multiple myeloma (MM) that induces T-cell-mediated killing of GPRC5-expressing MM cells through T-cell recruitment and activation, demonstrating antitumor activity.

Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity.

——

Animal Model:Female NSG mice with H929 cells Dosage:0.1-10 μg (0.005 mg/kg) Administration:Subcutaneous injection; on days 0, 3, 5, 7, and 10 Result:Completely blocked tumor formation at 1 μg and 10 μg doses. Animal Model:Female NSG mice with human MM cells Dosage:0.1-50 μg (0.005 mg/kg) Administration:Intravenous injection; on days 15, 18, 22, 24, 29, 32, and 36 Result:Significantly inhibited tumor growth by 65% at the dose of 1μg and showed significant anti-tumor activity at 10 and 50 μg with complete tumor regression.

——

GPCR/G Protein

Dopamine Receptor

Dopamine Receptor

——

——

2226212-40-2

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years